GF
ALNY icon

Gabelli Funds’s Alnylam Pharmaceuticals ALNY Stock Holding History

Gabelli Funds’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-550
Closed -$219K – 1267
2025
Q4 		$219K Buy
+550
New +$243K ﹤0.01% 1142
2019
Q4 		– Sell
-5,500
Closed -$442K – 1104
2019
Q3 		$442K Sell
5,500
-2,000
-27% -$158K ﹤0.01% 971
2019
Q2 		$544K Buy
+7,500
New +$575K ﹤0.01% 971

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Gabelli Funds's ALNY Position: Q1 2026 in Review

Gabelli Funds sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 550 shares — an estimated $219K sold.

Gabelli Funds first reported a position in ALNY in Q2 2019 and held it in 3 quarters. The position peaked at $544K in Q2 2019. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Gabelli Funds reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Gabelli Funds sold 550 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $219K.
  • Gabelli Funds first reported a position in Alnylam Pharmaceuticals in Q2 2019 and held it in 3 quarters.
  • Gabelli Funds's Alnylam Pharmaceuticals position peaked at $544K in Q2 2019.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Gabelli Funds's 13F filing for Q1 2026, filed 14 May 2026.